Abstract. Calbindin-D9k (CaBP-9k) is a cytosolic calcium-binding protein that is induced by estrogenic compounds possibly through estrogen receptors. We compared CaBP-9k mRNA expression in the uterus with uterotrophic response in immature rats exposed to methoxychlor (MC), an environmental chemical with estrogenic activity. MC was orally or subcutaneously administered to 3-week-old female Sprague-Dawley rats for 3 days. The weights of the uterus and vagina significantly increased in the oral treatment group at a dose of 50, 100 and 200 mg/kg, but those of the subcutaneous (SC) treatment group only increased at 200 mg/kg. Northern blot analysis showed that CaBP-9k mRNA expression was significantly induced in a dose-dependent manner at doses of 50, 100 and 200 mg/kg/ day in the oral treatment group. SC administration of MC induced significant expression at only a dose of 200 mg/kg/day; this was similar to the uterotrophic response. MC has an estrogenic effect on the uterus as shown by the increase in weight and induction of CaBP-9k mRNA expression, which were much greater following exposure via oral gavage than via the SC route. The strong correlation between the results of in vivo uterotrophic assay and CaBP-9k mRNA expression suggests that CaBP9k mRNA expression in the rat uterus may be used as an early gene marker for detection of the estrogenic effects of putative environmental chemicals.
delay of embryo implantation [38] . MC is categorized as a prototype endocrine disruptor or proestrogen that shows estrogenic activity due to its metabolites [39] [40] [41] [42] . The estrogenic effects of MC are believed to be caused by the action of its demethylated phenolic metabolites [16, 43] , which are major phase I metabolites catalysed by the cytochrome P450 monooxygenase system [44, 45] .
To assess the estrogenic potency and potential mechanism of action of MC, an environmentallyrelevant putative xenoestrogen, and evaluate the relative sensitivity of the method, we examined the uterotrophic responses and expression of CaBP-9k mRNA in the uteruses of immature rats via two routes of administration. This data provides new information on the potential estrogenic activity of MC in the in vivo model in relation to the expression of CaBP-9k mRNA in the uterus of rats and suggests that the expression of CaBP-9k mRNA can be used as a biomarker for investigating the estrogenicity of chemicals.
Materials and Methods

Experimental animals and treatment
Immature female Sprague-Dawley rats (18 days of age) were acquired from the Laboratory Animal Resources, National Institute of Toxicological Research, Korea Food and Drug Administration (KFDA, Seoul, Korea). The animals were housed in clear polycarbonate cages (3 animals/cage) with wood chips as bedding and were given a pellet rodent diet (Shinchon, Seoul, Korea) and tap water ad libitum under controlled environmental conditions, including a temperature of 21-25 C, relative humidity of 50-60%, a frequency of ventilation of more than 15 air exchanges/h, and a 12-h light/dark cycle (lights on: 0700-1900 h). All animals including the control animals used in this experiment were handled in an accredited KFDA animal facility in accordance with the guidelines for animal experiments of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International Animal Care Policies (Accredited Unit-KFDA: Unit Number-000996).
At 20 days of age, rats were randomly assigned to each group before treatment, to ensure that no significant differences in mean body weight were observed among the groups at the beginning of the study. The procedure was essentially based on the OECD protocol [20] . MC and corn oil were obtained from Sigma (St. Louis, MO, USA). The test compound was dissolved in corn oil for administration. The test compound was prepared daily before treatment. Rats were treated once daily with an oral or subcutaneous (SC) dose of MC (50, 100, or 200 mg/kg/day) for 3 days. The dose volume was 4 ml/kg body weight for oral exposure and 0.4 ml/kg for SC injection. Ethinyl estradiol (EE), which has a high affinity for the estrogen receptor, was used as a positive control chemical and corn oil only was used in the vehicle control group for this study.
Necropsy
Rats were observed daily for clinical signs and were euthanized 1 day after administration of the last dose of test substance in each sequence. Blood was collected from the abdominal vein under ether anesthesia and centrifuged at 3,000 rpm for 10 min at 4 C. The sera were stored at -80 C until use. The uterus was carefully dissected and trimmed of fascia and fat to avoid loss of the luminal contents. The vagina was removed from the uterus at the level of the uterine cervix and weighed. The vagina and uterus with the luminal contents (wet weight) were promptly weighed to the nearest 0.1 mg.
Northern blot assay
The CaBP-9k mRNA expression by MC was assessed by Northern blot analysis. In order to correlate increases in the uterine wet weight following administration of MC with ability to modulate the expression of the estrogen-sensitive gene, the CaBP-9k mRNA expression was analyzed using the same uterus as was used for the uterotrophic assay. For Northern blot analysis, the excised uterus was rapidly washed in cold sterile saline solution after weighing and was stored in a freezer (-80 C) after liquid nitrogen fixation. Total RNA was extracted using Trizol (Life Tech, R o c k v i l l e , M D , U S A ) a c c o r d i n g t o t h e manufacturer's suggested procedure, and the concentration of RNA was determined by the absorbance at 260 nm.
RNA was denatured by heating for 15 min at 65 C and UV cross-linked to the membrane using a gene cross-linker (Bio-Rad, Hercules, CA, USA). The membranes were prehybridized in 50% formamide, 5× SSPE, 5× Denhardt's solution, 0.1% SDS, and 0.1 mg/ml salmon sperm DNA for 3 h at 42 C. Radioactive labeled probes were prepared using a Random Labeling Kit (Life Tech). The [
32 P] d C T P -l a b e l e d p r o b e s w e r e a d d e d t o t h e hybridization solution and incubated for 16 h at 42 C. The membranes were washed three times at 42 C in 2× SSC and 0.1% SDS; at 54 C in 1× SSC and 0.1% SDS; and at 68 C in 0.1× SSC and 0.1% SDS. The membranes were then exposed to x-ray film (Eastman Kodak, Rochester, NY, USA). The film was scanned and analyzed using Molecular Analysis Program V1.5 (Gel Doc 1000, Bio-Rad).
For Northern blot analysis, 10 µg of total RNA was electrophoresed on 1% formaldehyde denaturing agarose gels for 90 min at 110 V, and 18S rRNA served as an indicator of the quantity of total RNA. RNA was then transferred from the agarose gel to a nylon membrane with a Vacuum Blotter (Bio-Rad). The CaBP-9k signal was detected by hybridizing the membrane with the radiolabeled probe and exposing it to X-ray film.
Procedure for extraction of MC from serum
Three serum samples were analyzed from each test group for determination of the concentration of MC in the blood. Extraction and instrumental analyses were conducted using the modified method of Frenich et al. [46] . Aliquots of 1 ml of blank serum were spiked by adding an appropriate volume of working standard solution and internal standard solution (ISTD), heptachlor, dissolved in n-hexane and equilibrated for 1 h at room temperature. After mixing with 1 ml of methanol for 2 min, 5 ml of a mixture of diethyl ether and nhexane (1:1) was added and mixed thoroughly for 2 min. Supernatants were collected by centrifuging at 3,000 rpm for 5 min, and the aqueous phase was extracted twice more with 5 ml of n-hexane-diethyl ether (1:1). Both supernatants, mixed with 1 g of sodium sulfate, were loaded onto a florisil SPE column and eluted with 2 ml of n-hexane. The combined organic phases were evaporated under liquid nitrogen gas at a slow flow rate. The pellets were resolved with 1 ml of a mixture of n-hexane and acetone (1:4) and transferred to an injection vial. and Chemstation software were used for GC-ECD analysis. The operation conditions were as follows: initial oven temperature 80 C (2 min) with the temperature increased by 10 C/min to 280 C (10 min); injector temperature of 260 C; detector temperature of 280 C; N 2 carrier gas at a flow rate of 1 ml/min; split mode operation (1:50); and an injection volume of 1 µl. A calibration curve (y= 0.6149x-0.004, r 2 is 0.9997) was calculated from the ratios of MC and heptachlor, and the concentration of the working standard was used to estimate the concentrations of MC in sera.
GC-ECD analysis
Data analysis
Means and standard deviations (SDs) were calculated for body and organ weights. The means were compared using Dunnett's test after one-way analysis of variance using SigmaStat V2.03 (SPSS, Chicago, IL, USA). Differences between values of P<0.05 were considered significant.
Results
Effects of MC on organ weight
No clinical signs or abnormalities were observed that were related to MC administration during the treatment period (data not shown). There were no significant differences in body weight at necropsy or the weights of the liver and ovaries between the MC-treated and control groups in spite of exposure, oral or SC, respectively (Table 1 ). Significant increases in the weights of the uterus and vagina were observed when rats were treated with EE for 3 days by the oral or SC route. Oral administration of MC significantly increased the uterus weights in a dose-related manner at MC doses of 50 (to 155% of the control), 100 (to 169% of the control), and 200 mg/kg/day (to 154% of the control), respectively. However, SC injection significantly increased the uterus weights at a dose of 200 mg/kg/day only (to 158% of the control). The weight of the vagina showed a similar change to that of the uterus. Oral administration significantly increased the vagina weights at doses of 50 (to 158% of the control), 100 (to 144% of the control), and 200 mg/kg/day (to 145% of the control), respectively. But, SC injection only significantly increased vagina weights at a dose of 200 mg/kg/day (to 133% of the control).
MC concentration in serum
T h e M C c o n c e n t r a t i o n s i n s e r u m w e r e determined by comparing the area ratio of the MC peak to the ISTD, heptachlor, with that of the external standard curve ( Table 2) . Recovery of MC in blank serum was 99.6%, which was determined by analyzing blank serum spiked with known c o n t e n t s o f M C a n d h e p t a c h l o r . T h e M C concentration in the sera of the oral treated group, accounting for 40%, was less than that of the subcutaneously injected group, respectively, at any dose.
Effects of MC on CaBP-9k mRNA level
A significant increase in CaBP-9k mRNA expression was observed when rats were treated with EE for 3 days when administered orally or s u b c u t a n e o u s l y ( F i g . 1 ) . W h e n i n j e c t e d subcutaneously, the CaBP-9k mRNA expression of the MC-treated group slightly increased in a dosedependent manner but was only significantly different at a dose of 200 mg/kg/day (to 260% of The data represents the mean ± SD from three different extraction experiments.
Fig. 1.
Northern blot analysis for CaBP-9k mRNA expression. Animals were treated with MC by oral gavage (PO) or subcutaneous injection (SC). Total RNA (10 µg) was subjected to Northern blot analysis. After hybridization with radio-labeled probes and exposure to x-ray film, the signal was analyzed by Molecular Analysis Program V1.5 (Gel Doc 1000, Bio-Rad). The values represent means ± SD (n=3). The means were compared using Dunnett's test after one-way analysis of variance. #. *: Significantly different from each vehicle control (P<0.05).
the control), the highest dose in this study. However, a more dramatic increase in CaBP-9k mRNA expression was observed in the uterus when rats were treated orally for 3 days with MC at doses of 50 (to 333% of the control), 100 (to 1,000% of the control), and 200 mg/kg/day (to 1,166% of the control) as compared to the control group.
Discussion
In the present study, treatment of immature rats with MC for 3 days induced dose-dependent increases in uterotrophic responses and CaBP-9k mRNA expression in the uterus. The magnitude of the changes in both the uterotrophic response and the CaBP-9k expression induced by MC was much greater following exposure via oral gavage than via SC injection. The CaBP-9k gene has been shown to be sensitive to estrogen and estrogenic chemicals, such as nonylphenol, octylphenol, bispehonol A, permethrin, and phthalates [25] [26] [27] [28] , and in this study, we examined whether the expression of CaBP-9k mRNA and protein could be used as a biomarker for detection of estrogenic chemicals in the rat. A strong correlation between in vivo uterotrophic response and CaBP-9k mRNA expression after exposure to MC, an environmental estrogen, provides evidence that CaBP-9k can be u s e d a s a m a r k e r g e n e f o r a s s a y i n g t h e estrogenicity of putative estrogenic compounds.
MC has been extensively studied in regard to its endocrine and reproductive toxicity in animals, and metabolites of MC have been reported to be more toxic than the parent compound, whereas the parent compound is essentially inactive [29-31, 43-45, 47] . In vitro and in vivo studies of MC metabolism have characterized several metabolites. Through cytochrome P450 metabolism in the liver, MC is metabolized to the predominant metabolites 1 , 1 , 1 -t r i c h l o r o -2 -( 4 -h y d r o x y p h e n y l ) -2 -( 4 -methoxyphenyl) ethane (mono-OH) and 1,1,1-trichloro-2,2-bis(4-hydroxyphenyl)ethane (HPTE) [48] . These polar metabolites are thought to mediate its estrogenic activity and induce the endocrine-disrupting capabilities of MC, indicating that MC per se is a proestrogen that must undergo hydroxylation in the liver to produce its estrogenic metabolites. Many investigations have focused on the ability of MC and its metabolites to bind to ERs α and β and act as endocrine disruptors. MC, mono-OH, and HPTE have all been shown to compete with 17β-estradiol (E2) for binding to ER to varying degrees; MC has very low affinity for ER, while mono-OH and HPTE have higher affinity for ER [29-31, 49, 50] . Both mono-OH and HPTE have b e e n s h o w n t o b e E R α a g o n i s t s a n d E R β antagonists [40, 51] , although they are much less potent than E2 as ERα agonists. The binding of an estrogen to the uterine cytosolic receptor has been proposed to be the initial step leading to estrogenic expression in the uterus [52, 53] . The compounds that bind ERs and induce or modulate an ERmediated response can be defined as estrogenic EDs. There are some reports that have examined the changes in genes or proteins for use as a biomarker for detection of EDs by simple methods in cultured cells or in selected tissues from exposed animals. Petit et al. [54] measured the induction of vitellogenin in trout hepatocyte cultures to identify estrogenic compounds, and Jakowlew et al. [58] reported rapid and strong induction of pS2 mRNA expression in human breast cells. CaBP-9k is a c y t o s o li c c a l c i u m -b i n d i n g p r o t e i n m a i n l y expressed in duodenum, placenta, and uterus, and the gene expression in the uterus is highly regulated by estrogen [24] . CaBP-9k synthesis fell drastically in the uterus of ovariectomized rats, but was greatly enhanced by low physiological doses of E 2 in a dose-dependent manner as assessed by CaBP-radioimmunoassay [56] . CaBP-9k protein was strongly up-regulated by alkyl phenols and estradiol in the uterus of immature rats through regulation of ERα mRNA expression in the rat uterus in terms of dose-and time-dependent response. Moreover, maternal exposure to estrogenic chemicals during late pregnancy also increased the expressions of CaBP-9k mRNA and protein in maternal and neonatal uteri, suggesting that these chemicals can easily pass through the placenta during pregnancy and affect the functions of neonatal reproductive tissues [25] [26] [27] [28] . These results suggest that environmental estrogens may regulate CaBP-9k mRNA expression through modulation of the transcriptional activity of the e s t r o g e n r e c e p t o r i n t h e s a m e m a n n e r a s endogenous steroids. Thus, the uterotrophic response and induction of mRNA expression of CaBP-9k in this study are considered to be due to the estrogenic effect of MC metabolites through ER in the uterus.
In the present study, the magnitude of the changes in CaBP-9k mRNA expression and uterine weight following oral exposure to MC was much greater than those induced following SC injection. Different pictures also emerged for the different r o u t e s o f e x p o s u r e i n t e r m s o f t h e M C concentration in the serum. MC is not excreted intact, and about 90% of it is excreted into feces in the form of metabolites in mice; the other 10% is excreted in urine [48, 57] . In this study, the MC concentrations in the sera of orally administered mice were about a third of the MC amount in the sera of subcutaneously administered mice when compared at any dose level. This may indicate that metabolism of MC occurs more rapidly via the oral route than the SC route and that estrogenic metabolites are produced in much greater quantities by liver enzymes. It is well known that differences in metabolic activation and/or elimination of test chemicals varies according to exposure route [58] . As in this study, previous work has shown a similar difference in the effect on uterine weight by MC via the oral and SC routes [20, 41, 59] . However, SC injection with 4-tertoctylphenol and bisphenol A resulted in a greater increase in uterine weight as compared to exposure by oral gavage [41] , suggesting the importance of choosing the proper administration route as it could significantly influence the outcome of the studies. I n c o n c l u s i o n , w e c o m p a r e d t h e 3 -d a y uterotrophic response and CaBP-9k mRNA expression in uterus following oral and SC exposure to MC and demonstrated that lower doses of MC can induce a uterotrophic response and an increased expression of CaBP-9k mRNA by oral administration as compared with the SC route. This data shows that the dosing route is a critical factor that can influence whether significant changes in uterotrophic response and CaBP-9k mRNA expression will be observed. Strong regulation of CaBP-9k mRNA expression by EE and MC and its correlation in our in vivo uterotrophic assay suggest that the CaBP-9k gene can be used as a u s e f u l b i o m a r k e r g e n e f o r a s s a y i n g t h e estrogenicity of putative estrogenic compounds when used in combination with classical assays.
